Amarin: Q1 Earnings Insights

 

Shares of Amarin Corp AMRN rose 2.5% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share rose 100.00% over the past year to ($0.00), which beat the estimate of ($0.05).

Revenue of $142,170,000 declined by 8.27% year over year, which missed the estimate of $147,100,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Apr 29, 2021

Time: 07:30 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2037/40926

Technicals

Company's 52-week high was at $9.25

Company's 52-week low was at $3.36

Price action over last quarter: down 21.07%

Company Profile

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its lead product includes Vascepa.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!